Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.
Johnson & Johnson announced a major milestone as the company launched a large-scale, international Phase III trial for the Covid-19 vaccine candidate JNJ-78436735.
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
EVERSANA launched ACTICS by EVERSANA, a technology-enabled solution to optimize end-to-end commercial success for life science companies.
GlaxoSmithKline opened a new $13 million research hub in London focused on artificial intelligence.
Blue Knight, a program created in partnership with Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA), chose seven startups from J&J’s global JLABS incubator network to participate in the fight against the world’s current Covid-19 pandemic and future ones.
According to a new study by Worldwide Partners, the effect that Covid-19 is having on digital health adoption is set to be transformative. The survey that was conducted shows technology is playing a crucial and growing role in mitigating the healthcare crisis, especially via telehealth.
As voice assistants and voice search have entered the mainstream, marketers need think about how and where their brands live within the voice landscape. From voice skills and actions to voice search and advertising, marketers have a few options to increase prominence in voice.
Virginia launched the first contact tracing app for the novel coronavirus in the United States that uses new technology from Apple Inc. and Alphabet Inc.’s Google.
Johnson & Johnson’s Janssen Pharmaceutical Companies entered into an agreement with the U.S. government for the large-scale domestic manufacturing and delivery in the United States of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use following approval or Emergency Use Authorization by the Food and Drug Administration.
